Angelos Hatzakis1, Vana Sypsa1, Dimitrios Paraskevis1, Georgios Nikolopoulos2, Chrissa Tsiara3, Katerina Micha4, Anastasios Panopoulos4, Meni Malliori5, Mina Psichogiou6, Anastasia Pharris7, Lucas Wiessing8, Marita van de Laar9, Martin Donoghoe10, Douglas D Heckathorn11, Samuel R Friedman12, Don C Des Jarlais13. 1. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece. 2. IAS/NIDA Fellow, Hellenic Center for Diseases Prevention and Control, Athens, Greece. 3. Hellenic Centre for Diseases Control and Prevention, Athens, Greece. 4. Organization Against Drugs, Athens, Greece. 5. Medical School, University of Athens, Athens, Greece. 6. Department of Propedeutic Medicine, Medical School, University of Athens, Athens, Greece. 7. European Centre for Disease Prevention and Control, Stockholm, Sweden. 8. European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal. 9. Consultant Public Health, Utrecht, the Netherlands. 10. World Health Organization Regional Office for Europe, Copenhagen, Denmark. 11. Cornell University, Ithaca, NY, USA. 12. National Development and Research Institutes, New York, USA. 13. Beth Israel Medical Center, New York, USA.
Abstract
AIMS: To (i) describe an intervention implemented in response to the HIV-1 outbreak among people who inject drugs (PWIDs) in Greece (ARISTOTLE programme), (ii) assess its success in identifying and testing this population and (iii) describe socio-demographic characteristics, risk behaviours and access to treatment/prevention, estimate HIV prevalence and identify risk factors, as assessed at the first participation of PWIDs. DESIGN: A 'seek, test, treat, retain' intervention employing five rounds of respondent-driven sampling. SETTING: Athens, Greece (2012-13). PARTICIPANTS: A total of 3320 individuals who had injected drugs in the past 12 months. INTERVENTION: ARISTOTLE is an intervention that involves reaching out to high-risk, hard-to-reach PWIDs ('seek'), engaging them in HIV testing and providing information and materials to prevent HIV ('test') and initiating and maintaining anti-retroviral and opioid substitution treatment for those testing positive ('treat' and 'retain'). MEASUREMENTS: Blood samples were collected for HIV testing and personal interviews were conducted. FINDINGS: ARISTOTLE recruited 3320 PWIDs during the course of 13.5 months. More than half (54%) participated in multiple rounds, resulting in 7113 visits. HIV prevalence was 15.1%. At their first contact with the programme, 12.5% were on opioid substitution treatment programmes and the median number of free syringes they had received in the preceding month was 0. In the multivariable analysis, apart from injection-related variables, homelessness was a risk factor for HIV infection in male PWIDs [odds ratio (OR) yes versus no = 1.89, 95% confidence interval (CI) = 1.41, 2.52] while, in female PWIDS, the number of sexual partners (OR for > 5 versus one partner in the past year = 4.12, 95% CI = 1.93, 8.77) and history of imprisonment (OR yes versus no = 2.76, 95% CI = 1.43, 5.31) were associated with HIV. CONCLUSIONS: In Athens, Greece, the ARISTOTLE intervention for identifying HIV-positive people among people who inject drugs (PWID) facilitated rapid identification of a hidden population experiencing an outbreak and provided HIV testing, counselling and linkage to care. According to ARISTOTLE data, the 2011 HIV outbreak in Athens resulted in 15% HIV infection among PWID. Risk factors for HIV among PWID included homelessness in men and history of imprisonment and number of sexual partners in women.
AIMS: To (i) describe an intervention implemented in response to the HIV-1 outbreak among people who inject drugs (PWIDs) in Greece (ARISTOTLE programme), (ii) assess its success in identifying and testing this population and (iii) describe socio-demographic characteristics, risk behaviours and access to treatment/prevention, estimate HIV prevalence and identify risk factors, as assessed at the first participation of PWIDs. DESIGN: A 'seek, test, treat, retain' intervention employing five rounds of respondent-driven sampling. SETTING: Athens, Greece (2012-13). PARTICIPANTS: A total of 3320 individuals who had injected drugs in the past 12 months. INTERVENTION: ARISTOTLE is an intervention that involves reaching out to high-risk, hard-to-reach PWIDs ('seek'), engaging them in HIV testing and providing information and materials to prevent HIV ('test') and initiating and maintaining anti-retroviral and opioid substitution treatment for those testing positive ('treat' and 'retain'). MEASUREMENTS: Blood samples were collected for HIV testing and personal interviews were conducted. FINDINGS: ARISTOTLE recruited 3320 PWIDs during the course of 13.5 months. More than half (54%) participated in multiple rounds, resulting in 7113 visits. HIV prevalence was 15.1%. At their first contact with the programme, 12.5% were on opioid substitution treatment programmes and the median number of free syringes they had received in the preceding month was 0. In the multivariable analysis, apart from injection-related variables, homelessness was a risk factor for HIV infection in male PWIDs [odds ratio (OR) yes versus no = 1.89, 95% confidence interval (CI) = 1.41, 2.52] while, in female PWIDS, the number of sexual partners (OR for > 5 versus one partner in the past year = 4.12, 95% CI = 1.93, 8.77) and history of imprisonment (OR yes versus no = 2.76, 95% CI = 1.43, 5.31) were associated with HIV. CONCLUSIONS: In Athens, Greece, the ARISTOTLE intervention for identifying HIV-positive people among people who inject drugs (PWID) facilitated rapid identification of a hidden population experiencing an outbreak and provided HIV testing, counselling and linkage to care. According to ARISTOTLE data, the 2011 HIV outbreak in Athens resulted in 15% HIV infection among PWID. Risk factors for HIV among PWID included homelessness in men and history of imprisonment and number of sexual partners in women.
Authors: S R Friedman; A Neaigus; B Jose; R Curtis; M Goldstein; G Ildefonso; R B Rothenberg; D C Des Jarlais Journal: Am J Public Health Date: 1997-08 Impact factor: 9.308
Authors: Alla V Shaboltas; Olga V Toussova; Irving F Hoffman; Robert Heimer; Sergei V Verevochkin; Robert W Ryder; Kaveh Khoshnood; Tom Perdue; Benoit R Masse; Andrei P Kozlov Journal: J Acquir Immune Defic Syndr Date: 2006-04-15 Impact factor: 3.731
Authors: Mina Psichogiou; George Giallouros; Katerina Pantavou; Eirini Pavlitina; Martha Papadopoulou; Leslie D Williams; Andria Hadjikou; Eleni Kakalou; Athanasios Skoutelis; Konstantinos Protopapas; Anastasia Antoniadou; George Boulmetis; Dimitrios Paraskevis; Angelos Hatzakis; Samuel R Friedman; Georgios K Nikolopoulos Journal: AIDS Care Date: 2019-04-02
Authors: Dimitrios Paraskevis; Georgios K Nikolopoulos; Vana Sypsa; Mina Psichogiou; Katerina Pantavou; Evangelia Kostaki; Timokratis Karamitros; Dimitra Paraskeva; John Schneider; Melpomeni Malliori; Samuel R Friedman; Don C Des Jarlais; Georgios L Daikos; Angelos Hatzakis Journal: Infect Genet Evol Date: 2018-04-10 Impact factor: 3.342
Authors: Foteini Giannou; Georgios K Nikolopoulos; Katerina Pantavou; Vassiliki Benetou; Maria Kantzanou; Vana Sypsa; Leslie D Williams; Samuel R Friedman; Angelos Hatzakis Journal: Curr HIV Res Date: 2017 Impact factor: 1.581
Authors: Dimitrios Paraskevis; Evangelia Kostaki; Georgios K Nikolopoulos; Vana Sypsa; Mina Psichogiou; Julia Del Amo; Ioannis Hodges-Mameletzis; Dimitra Paraskeva; Athanasios Skoutelis; Meni Malliori; Leslie Williams; Samuel R Friedman; Georgios L Daikos; Angelos Hatzakis Journal: Clin Infect Dis Date: 2017-11-29 Impact factor: 9.079